Patient Survey Explores Real World Burden of Idiopathic Hypersomnia
Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.
March is an important month for us at Jazz. As a leader in sleep medicine, the month served as an awareness opportunity for those living with sleep disorders, as well as their caregivers, healthcare providers and our advocacy partners.
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Please select and enter the required fields on the form below. We need this information to process your request and to take necessary steps to verify your identity.
We will contact you if we need any additional information
Thank you for contacting Jazz Pharmaceuticals Corporate Development & Partnering
Sending data...
Contact Corporate Development / Partnering
Personal Information(All fields are required)
Please provide details on this opportunity
The information on this page is intended for visitors in
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.
You are now leaving www.JazzPharma.com. Thank you for visiting. The information on the website you are entering is intended for visitors in the United States only.
